Release of somatostatin-like immunoreactivity from incubated rat hypothalamus and cerebral cortex. Effects of glucose and glucoregulatory hormones.

Somatostatin (SRIF) is localized in the hypothalamus, extrahypothalamic brain, and throughout the gastrointestinal tract. Release of gastrointestinal SRIF-like immunoreactivity (SRIF-LI) is under nutrient regulation but the effect of nutrients on neural SRIF-LI is unknown. The present studies examined the effects of glucose uptake and metabolism and hormones influencing glucose disposition on SRIF-LI release from medial basal hypothalamus (MBH) and cerebral cortex (Cx) incubated in Krebs-Ringer bicarbonate containing bacitracin. After a preincubation to achieve stable secretion, tissues were incubated for 20 min in 14 mM glucose (basal) and then, for 20 min in fresh medium with test materials. MBH SRIF-LI release was inversely related to medium glucose concentration with release in the absence of glucose (235+/-42 pg/MBH per 20 min) more than five times that in the presence of 25 mM glucose (46+/-4 pg/20 min). In the presence of 14 mM glucose MBH SRIF-LI release was stimulated above basal by agents interfering with glucose uptake including 3-O-methyl-d-glucose (42 mM; 70+/-5 vs. 42+/-3 pg/20 min, P < 0.05), phlorizin (50 mM; 351+/-63 vs. 29+/-2 pg/20 min, P < 0.001) or cytochalasin B (20 muM; 110+/-7 vs. 22+/-2 pg/20 min, P < 0.001). Inhibition of glucose metabolism by 2-deoxy-d-glucose resulted in dose-related stimulation of MBH SRIF-LI release (maximal at 28 mM; 201+/-28 pg/20 min vs. 32+/-4 pg/20 min, P < 0.001). Viability of MBH was unimpaired by incubation in the absence of glucose or following exposure to 2-deoxy-d-glucose as determined by retention of SRIF-LI responsiveness to stimulation by potassium (60 mM) or neurotensin (5 muM). In contrast, Cx SRIF-LI release was slightly inhibited by decreases in medium glucose and unaffected by inhibition of glucose uptake or metabolism. These results provide evidence for nutrient regulation of MBH but not Cx SRIF-LI release and may explain inhibition of growth hormone seen in the rat in response to hypoglycemia. Insulin (10 nM-1 muM) stimulated MBH but not Cx SRIF-LI release while glucagon was without effect. Our previous demonstration that MBH SRIF-LI release was stimulated by somatomedin-C, but not insulin at physiologic concentrations, is consistent with an action of insulin through the somatomedin-C receptor at the doses studied. Our studies indicate a regional specificity for the control of SRIF secretion within the brain and suggests the possibility of a role for hypothalamic SRIF in metabolic regulation.

[1]  M. Sheppard,et al.  STIMULATION BY GROWTH HORMONE OF SOMATOSTATIN RELEASE FROM THE RAT HYPOTHALAMUS IN VITRO , 1978, Clinical endocrinology.

[2]  R. Unger,et al.  Evidence for a role of splanchnic somatostatin in the homeostasis of ingested nutrients. , 1979, Endocrinology.

[3]  L. Frohman,et al.  Effects of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution. , 1981, Endocrinology.

[4]  L. Lazarus,et al.  SOMATOMEDINS , 1975, The Medical journal of Australia.

[5]  R. Unger,et al.  Evidence for a role of free fatty acids in the regulation of somatostatin secretion in normal and alloxan diabetic dogs. , 1980, The Journal of clinical investigation.

[6]  Y. Goto,et al.  Effect of ventromedial hypothalamic lesions on the secretion of somatostatin, insulin, and glucagon by the perfused rat pancreas. , 1980, Metabolism: clinical and experimental.

[7]  A. Kastin,et al.  DIRECT INHIBITION OF GASTRIC ACID AND PEPSIN SECRETION BY GROWTH-HORMONE RELEASE-INHIBITING HORMONE IN CATS , 1975, The Lancet.

[8]  L. Frohman,et al.  The effect of alterations in the pituitary-thyroid axis on hypothalamic content and in vitro release of somatostatin-like immunoreactivity. , 1980, Endocrinology.

[9]  A. Schally,et al.  Stimulated release of hypothalamic growth hormone-releasing activity by morphine and pentobarbital , 1977, Molecular and Cellular Endocrinology.

[10]  D. Gilboe,et al.  Cytochalasin B inhibition of brain glucose transport and the influence of blood components on inhibitor concentration. , 1977, Biochimica et biophysica acta.

[11]  C. J. Goodner,et al.  Somatostatin: Hypothalamic Inhibitor of the Endocrine Pancreas , 1974, Science.

[12]  M. Hasegawa,et al.  Physiologic Role of Somatostatin Insulin Release from Rat Islets Treated by Somatostatin Antiserum , 1977, Diabetes.

[13]  N. Barden,et al.  Stimulation of glucagon release by addition of anti-stomatostatin serum to islets of Langerhans in vitro. , 1977, Endocrinology.

[14]  P. Lacy,et al.  Effects of cytochalasins B and D on alloxan inhibition of insulin release. , 1975, Biochemical and biophysical research communications.

[15]  P. J. Randle,et al.  Regulation of Glucose Uptake by Muscle , 1962 .

[16]  M. Jobin,et al.  Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. , 1976, Biochemical and biophysical research communications.

[17]  S. Efendić,et al.  Effect of Somatostatin on Intestinal Motility , 1978, Acta radiologica: diagnosis.

[18]  C. Park,et al.  IDENTIFICATION OF A MOBILE CARRIER-MEDIATED SUGAR TRANSPORT SYSTEM IN MUSCLE. , 1964, The Journal of biological chemistry.

[19]  A. Schally,et al.  Increase in basal and thyrotropin-releasing hormone (TRH)-stimulated secretion of thyrotropin (TSH) by passive immunization with antiserum to somatostatin in rats. , 1976, Endocrinology.

[20]  V. Schusdziarra Somatostatin - A Regulatory Modulator Connecting Nutrient Entry and Metabolism , 1980, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[21]  J. Brown,et al.  Splanchnic somatostatin: a hormonal regulator of nutrient homeostasis. , 1980, Science.

[22]  M. Berelowitz,et al.  Potassium stimulated calcium dependent release of immunoreactive somatostatin from incubated rat hypothalamus , 1978, Journal of neurochemistry.

[23]  L. Frohman,et al.  Release of somatostatin and thyrotropin-releasing hormone from rat hypothalamic fragments in vitro. , 1980, Endocrinology.

[24]  M. Dubois Immunoreactive somatostatin is present in discrete cells of the endocrine pancreas. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R L Hintz,et al.  Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. , 1981, Science.

[26]  S. Reichlin,et al.  Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat. , 1978, Endocrinology.

[27]  K. Polonsky,et al.  Reduction in Portal Vein Blood Flow by Somatostatin , 1979, Diabetes.

[28]  J. Oliver,et al.  INHIBITION OF CHOLECYSTOKININ-PANCREOZYMIN RELEASE BY SOMATOSTATIN , 1977, The Lancet.

[29]  M. Berelowitz,et al.  A RADIOIMMUNOASSAY FOR GROWTH HORMONE RELEASE‐INHIBITING HORMONE: METHOD AND QUANTITATIVE TISSUE DISTRIBUTION , 1976, Clinical endocrinology.

[30]  S. Raptis,et al.  Effects of Somatostatin on Exocrine and Endocrine Pancreatic Function Stimulated by Intestinal Hormones in Man* , 1976, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[31]  J. Rehfeld,et al.  Somatostatin cell processes as pathways for paracrine secretion. , 1979, Science.

[32]  R. Unger,et al.  Pancreatic and gastric release of somatostatinlike immunoreactivity during intestinal phase of a meal. , 1979, The American journal of physiology.

[33]  J. Epelbaum,et al.  Antiserum to somatostatin reverses starvation-induced inhibition of growth hormone but not insulin secretion. , 1978, Endocrinology.